New eye drops aim to replace reading glasses – but are they safe Long-Term?

NCT ID NCT05753189

Completed Disease control Sponsor: LENZ Therapeutics, Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 study tested the long-term safety of LNZ101 eye drops, a combination of aceclidine and brimonidine, in 362 adults aged 45-75 with presbyopia (age-related blurry near vision). Participants used the drops regularly and were monitored for side effects. The study is complete, and results will show how safe the drops are for ongoing use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Aceclidine and brimonidine combination eye drops
What this could lead to: If successful, this could confirm that the eye drops are safe for long-term use to temporarily improve near vision without glasses.
What could go wrong: This is a safety study, not designed to prove effectiveness. Side effects like eye irritation or redness may occur, and the drops only work while they are being used.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

eye disorder myopia presbyopia refractive error

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EYE DISEASES NEAR VISION PRESBYOPIA REFRACTIVE ERROR

Contacts and locations

Locations

Site #301

Overland Park, Kansas, 66210, United States
Site #302

Chandler, Arizona, 85224, United States
Site #303

Garden Grove, California, 92843, United States
Site #304

Santa Barbara, California, 93105, United States
Site #306

Petaluma, California, 94954, United States
Site #307

Pittsburg, Kansas, 66762, United States
Site #308

Littleton, Colorado, 80120, United States
Site #309

Mt. Dora, Florida, 32757, United States
Site #310

Fargo, North Dakota, 58103, United States
Site #311

Smyrna, Tennessee, 37167, United States
Site #312

Cranberry Township, Pennsylvania, 16066, United States
Site #313

Glendale, California, 91204, United States
Site #314

El Paso, Texas, 79902, United States
Site #315

Memphis, Tennessee, 38104, United States
Site #316

Danbury, Connecticut, 06810, United States
Site #317

Rock Island, Illinois, 61201, United States
Site #318

San Antonio, Texas, 78229, United States
Site #319

Crystal River, Florida, 34429, United States
Site #320

Mesa, Arizona, 85202, United States
Site #321

Phoenix, Arizona, 85032, United States
Site #322

Newport Beach, California, 92663, United States
Site #323

Powell, Ohio, 43065, United States
Site #324

Louisville, Kentucky, 40206, United States
Site #325

St Louis, Missouri, 63128, United States
Site #326

Dothan, Alabama, 36301, United States
Site #327

San Antonio, Texas, 78229, United States
Site #328

Phoenix, Arizona, 85053, United States
Site #329

Cincinnati, Ohio, 45242, United States
Site #330

Kansas City, Missouri, 64154, United States
Site #331

Sun City, Arizona, 85351, United States
Site #332

West Fargo, North Dakota, 58078, United States
Site #333

Eugene, Oregon, 97401, United States
Site #334

La Jolla, California, 92037, United States
Site #335

Bozeman, Montana, 59718, United States
Site #336

Alexandria, Minnesota, 56308, United States
Site #337

Rancho Cordova, California, 95670, United States
Site #338

Scottsdale, Arizona, 85260, United States
Site #339

Morrow, Georgia, 30260, United States
Site #340

Northbrook, Illinois, 60062, United States
Site #341

Dover, New Jersey, 07801, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.